CHRS vs IBO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Sell and IBO is a Sell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CHRS’s FA Score shows that 0 FA rating(s) are green whileIBO’s FA Score has 1 green FA rating(s).
- CHRS’s FA Score: 0 green, 5 red.
- IBO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CHRS’s TA Score shows that 6 TA indicator(s) are bullish.
- CHRS’s TA Score: 6 bullish, 2 bearish.
Price Growth
CHRS (@Biotechnology) experienced а -8.71% price change this week, while IBO (@Biotechnology) price change was +3.10% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.
Reported Earning Dates
CHRS is expected to report earnings on Feb 27, 2025.
Industries' Descriptions
@Biotechnology (-8.58% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CHRS | IBO | CHRS / IBO | |
| Capitalization | 85.7M | 34.4M | 249% |
| EBITDA | 12.3M | N/A | - |
| Gain YTD | -77.658 | -99.230 | 78% |
| P/E Ratio | N/A | 29.51 | - |
| Revenue | 308M | N/A | - |
| Total Cash | 159M | N/A | - |
| Total Debt | 270M | N/A | - |
CHRS | IBO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 95 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 91 | |
PRICE GROWTH RATING 1..100 | 93 | 62 | |
P/E GROWTH RATING 1..100 | 67 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 30 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IBO's Valuation (20) in the null industry is significantly better than the same rating for CHRS (90) in the Biotechnology industry. This means that IBO’s stock grew significantly faster than CHRS’s over the last 12 months.
IBO's Profit vs Risk Rating (100) in the null industry is in the same range as CHRS (100) in the Biotechnology industry. This means that IBO’s stock grew similarly to CHRS’s over the last 12 months.
IBO's SMR Rating (91) in the null industry is in the same range as CHRS (100) in the Biotechnology industry. This means that IBO’s stock grew similarly to CHRS’s over the last 12 months.
IBO's Price Growth Rating (62) in the null industry is in the same range as CHRS (93) in the Biotechnology industry. This means that IBO’s stock grew similarly to CHRS’s over the last 12 months.
CHRS's P/E Growth Rating (67) in the Biotechnology industry is somewhat better than the same rating for IBO (100) in the null industry. This means that CHRS’s stock grew somewhat faster than IBO’s over the last 12 months.
| CHRS | |
|---|---|
| RSI ODDS (%) | 3 days ago 77% |
| Stochastic ODDS (%) | 3 days ago 83% |
| Momentum ODDS (%) | 3 days ago 78% |
| MACD ODDS (%) | 3 days ago 79% |
| TrendWeek ODDS (%) | 3 days ago 86% |
| TrendMonth ODDS (%) | 3 days ago 86% |
| Advances ODDS (%) | 10 days ago 73% |
| Declines ODDS (%) | 3 days ago 86% |
| BollingerBands ODDS (%) | 5 days ago 88% |
| Aroon ODDS (%) | 3 days ago 90% |
IBO and
Correlation & Price change
A.I.dvisor indicates that over the last year, IBO has been loosely correlated with BMRN. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IBO jumps, then BMRN could also see price increases.
| Ticker / NAME | Correlation To IBO | 1D Price Change % | ||
|---|---|---|---|---|
| IBO | 100% | +19.12% | ||
| BMRN - IBO | 59% Loosely correlated | -3.32% | ||
| ITOS - IBO | 44% Loosely correlated | -2.72% | ||
| LPCN - IBO | 27% Poorly correlated | -6.14% | ||
| ADAG - IBO | 24% Poorly correlated | -6.90% | ||
| CHRS - IBO | 24% Poorly correlated | -3.70% | ||
More | ||||